HC Wainwright Forecasts Senseonics FY2030 Earnings

Senseonics Holdings, Inc. (NYSE:SENS) – Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for Senseonics in a research report issued on Tuesday, March 3rd. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of ($1.19) for the year. HC Wainwright has a “Buy” rating and a $18.50 price target on the stock. The consensus estimate for Senseonics’ current full-year earnings is ($0.14) per share.

Other research analysts have also issued research reports about the stock. Stifel Nicolaus set a $9.00 price target on shares of Senseonics in a research report on Tuesday. TD Cowen reissued a “buy” rating on shares of Senseonics in a report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $22.70.

Senseonics Price Performance

NYSE:SENS opened at $6.11 on Wednesday. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a 50-day moving average of $7.20 and a 200-day moving average of $7.54. Senseonics has a 52 week low of $5.25 and a 52 week high of $15.74. The company has a market capitalization of $255.21 million, a price-to-earnings ratio of -47.00 and a beta of 0.90.

Institutional Trading of Senseonics

Several hedge funds have recently modified their holdings of SENS. GSK plc bought a new position in shares of Senseonics in the fourth quarter valued at approximately $60,000. Townsend Asset Management Corp NC ADV acquired a new stake in Senseonics during the 4th quarter valued at $60,000. Sanctuary Advisors LLC bought a new position in Senseonics in the 4th quarter valued at $71,000. Captrust Financial Advisors acquired a new position in Senseonics in the fourth quarter worth $77,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Senseonics during the fourth quarter worth $82,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Key Senseonics News

Here are the key news stories impacting Senseonics this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and an $18.50 price target on SENS, which signals the analyst sees upside from current levels despite the cuts to earnings estimates. MarketBeat
• Neutral Sentiment: The same report added a FY2030 EPS forecast (loss of $1.19), giving a longer-term model from the analyst — useful for modeling recovery timing but not an immediate catalyst. MarketBeat
• Negative Sentiment: HC Wainwright cut multiple near-term estimates: Q1 2026 to ($0.67) from ($0.49), Q2 to ($0.72) from ($0.54), Q3 to ($0.78) from ($0.60) and Q4 to ($0.78) from ($0.64). Annual forecasts were also reduced — FY2026 to ($2.95) from ($2.27), FY2027 to ($3.12) from ($2.26), FY2028 to ($2.72) from ($1.88) and FY2029 to ($2.03) from ($1.32). Those deeper loss projections increase downside risk, help explain selling pressure, and could raise the need for additional financing. MarketBeat

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.